Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27505825 | 0.84 | PNMT (0.48) | FOLH1SLC7A5MEN1KMT2AMAOB | |
| SCHEMBL27506588 | 0.83 | CA12 (0.47) | MEN1KMT2A | |
| SCHEMBL27487295 | 0.83 | LMNA (0.48) | MEN1KMT2A | |
| SCHEMBL27665676 | 0.79 | SLC1A1 (0.43) | SLC1A1SLC7A5PPARGPPARAMEN1 | |
| SCHEMBL9816405 | 0.78 | PPARG (0.40) | PPARGPPARAKMT2AMAOA | |
| SCHEMBL29263663 | 0.78 | HDAC6 (0.52) | — | |
| SCHEMBL9235143 | 0.78 | FFAR1 (0.42) | SLC1A1MEN1KMT2A | |
| SCHEMBL901672 | 0.77 | TAAR1 (0.53) | MAOB | |
| SCHEMBL27505437 | 0.77 | SLC1A1 (0.47) | SLC1A1SLC7A5PPARGPPARAMAOB | |
| SCHEMBL27488016 | 0.76 | SLC1A1 (0.55) | SLC1A1PPARGPPARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | claimed |
| CN-101862317-A | The pregabalin derivant that is used for the treatment of fibromyalgia and other disease | WARNER LAMBERT CO | 2010-10-20 | — | — | CN | disclosed |
| CN-101283995-A | Different pharmaceutical uses alpha2delta ligands | WARNER LAMBERT CO (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-1310872-C | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1878546-A | Combination comprising an alpha-2 delta ligand and an SSRI and/or SNRI for the treatment of depression and anxiety | WARNER LAMBERT CO (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1726015-A | Alpha 2 delta ligands for different pharmaceutical uses | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1726023-A | Pregabalin derivatives for the treatment of fibromyalgia and other diseases | WARNER LAMBERT CO (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1678298-A | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1660779-A | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-08-31 | — | — | CN | disclosed |
| CN-1625393-A | Alpha 2 delta ligands to treat tinnitus | WARNER LAMBERT CO (US) | 2005-06-08 | — | — | CN | disclosed |
| CN-1196671-C | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2005-04-13 | — | — | CN | disclosed |
| CN-1355784-A | Mono-and disubstituted 3-propyl-gamma-aminobutyric acids | WARNER LAMBERT CO (US) | 2002-06-26 | — | — | CN | disclosed |